A Facebook Like Became an Endorsement: BergaMet

what did fda treat as an endorsement in the bergamet letter?

FDA treated a Facebook 'like' as a brand endorsement in its November 14, 2022 warning letter to BergaMet North America LLC (MARCS-CMS 636315), over a bergamot supplement called Cholesterol Command. Under a March 14, 2022 post, the agency wrote that BergaMet had endorsed customer replies and, separately, that 'You also endorsed the following responses to your post by liking them.'

We checked that sentence against the rest of the letter, and the like was the smallest item in a much longer stack. FDA had already cited the product's own name, the express claim that it 'is clinically proven to improve cholesterol levels. It reduces LDL,' a money-back guarantee tied to lab results, and a Walmart listing describing it as 'a bergamot supplement for high cholesterol.'

The like was the smallest thing on the page, and it still counted.

Cholesterol is one of the niches where FDA runs coordinated same-day letter sweeps, which is part of why raw warning-letter counts make a poor risk ranking across supplement verticals — volume tracks enforcement cadence, not ceiling.

how does liking a comment become claim-making?

Liking a comment becomes claim-making because FDA judges intended use from the whole marketing picture, not from who typed the words. Under 21 CFR 201.128, intended use 'may... be shown by labeling claims, advertising matter, or oral or written statements,' and separately by 'the circumstances surrounding the distribution of the article' — a like is exactly that kind of circumstance.

FDA had already built the specific test for this niche before it ever reached the comment section. In the same rulemaking record, the agency said it 'will review all cholesterol claims to determine whether the labeling as a whole implies that the product is intended to lower elevated cholesterol levels' — a like sits inside that whole, the same as a headline or a bottle name.

This treatment of organic engagement isn't unique to Facebook. In a different 2021 letter, FDA quoted Instagram hashtags as evidence of intended use for a diabetes supplement, reading a caption the same way it reads paid creative, months before this like ever went up.

which customer comments did fda quote back at the brand?

FDA quoted two customer replies by name, and flagged that BergaMet had liked further responses without transcribing every one of them. Under the March 14, 2022 post, one commenter wrote that the product '…brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!' — and BergaMet's own account replied 'that is AMAZING Lori!'

We could not confirm the exact wording of that third row from the material available to us; the full letter attachment on fda.gov would settle it.

why is a statin-replacement comment a substitute-for-therapy claim?

The second comment FDA quoted put it more plainly: a customer wrote 'That's what I use I stopped taking my prescription and my lab test number are great.' That sentence is a substitute-for-therapy claim under 21 CFR 101.93(g)(2)(vi), which reaches any statement that a product 'is a substitute for a product that is a therapy for a disease' — regardless of who wrote it, and a statin is therapy for a disease FDA itself has named.

That disease designation isn't a stretch. FDA's own 2000 rulemaking states that 'elevated cholesterol (hypercholesterolemia)' is a disease in its own right, not a risk factor for one — which is also why 'lowers cholesterol, however qualified' has never been an available structure/function claim for a supplement.

By the time FDA reached the comment section, BergaMet had already stacked four separate triggers under 101.93(g)(2): the product name, the express LDL claim, the results-based guarantee, and now a customer's own substitution story. Each is independently sufficient. Together they read as one continuous claim running from the headline to the comment thread.

does replying without agreeing carry the same risk?

Probably not, and the letter doesn't test that question directly — FDA cited an active reply and an active like, not silence. Both are affirmative gestures a reasonable reader would take as agreement, which tracks the same logic the FTC's endorsement rules use before treating a third party's words as the advertiser's own.

Here is the part most brands get backwards: the risk almost certainly does not start at the like. FDA has separately cited unmoderated testimonials sitting on a brand's own product page or Facebook About section as drug evidence with no reply and no like anywhere in the citation — an eye-supplement seller and a diabetes-supplement seller both drew that treatment in unrelated letters years apart, where a customer review simply sat on the page and FDA quoted it. The page hosted the words, and hosting was enough. Waiting to react until a comment gets traction, on the theory that silence is neutral, treats moderation as optional in exactly the place the warning-letter record treats it as continuous.

Hosting is a lower bar than most compliance checklists assume.

how should community management be run on a health offer?

Community management on a health offer should treat every reply, like, and pin the way copy review treats a headline. A comment naming a competitor's prescription drug, a diagnosis, or a stopped prescription needs the same sign-off your landing page claims get, before anyone on the brand account touches it.

• Route any comment naming a drug, a diagnosis, or 'I stopped taking my prescription' to whoever clears your ad copy — before you reply, like, or pin it.
• Never reply with agreement or enthusiasm to a comment claiming the product treats, cures, or substitutes for a therapy; a neutral acknowledgment is safer than a thumbs-up.
• Log who holds posting and liking access on the brand's pages — [affiliate and freelance social managers create the same liability the advertiser carries](/niches/your-affiliate-s-ad-your-warning-letter), even when they never touch your ad account.
• Disclose any material connection behind a comment or review you solicited with free product or payment, under the FTC's testimonial rules at [16 CFR Part 255](https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255).

what moderation policy would have prevented this citation?

A written rule against replying to or liking disease-adjacent comments would have prevented this specific citation, though not the rest of the letter. The Lori comment and the prescription-stopping comment could have stood unanswered on the page — FDA's citation depended on BergaMet's like and reply, not on the comment simply existing there.

Removing a comment that makes an illegal health claim is a compliance action, not the review suppression the FTC's 2024 rule targets. The Reviews and Testimonials Rule at 16 CFR Part 465 bars suppressing genuine negative reviews through threats or fake counter-claims; it doesn't protect a customer's statin-substitution story from being taken down.

This runs against a common instinct on social teams: like the positive ones, ignore the rest. Whether likes and comments actually predict which ad wins is a separate question from whether liking any single one is safe, and the two get conflated far too often.

We looked for a comparable letter with a plain like and no reply attached, and found none — this is the cleanest example on record.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as Meta Ad Library, Meta advertising standards, and FTC health claims guidance. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Weight Loss Supplement in Bangladesh: The Practical Version, Brain Booster Supplement Price in Bangladesh, GLP-1 Affiliate Marketing Intelligence, Weight loss VSL intelligence, and CPC, CPM, and ROAS benchmarks by niche. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.